# An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

> **NCT05649748** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Insmed Incorporated** · enrollment: 91 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Treprostinil Palmitil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05649748
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-07
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05649748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05649748, "An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05649748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*